Evidence map›Paper›PMID 40708351›Full record

ArticleAmerican journal of hypertension2025

Soluble Receptor for Advanced Glycation End Products and Incident Hypertension in REGARDS.

Sarah D R Krumholz, Mary Cushman, Nels C Olson, D Leann Long, Suzanne E Judd, Virginia J Howard, Timothy B Plante

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sarah D R KrumholzLarner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Mary CushmanLarner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Nels C OlsonLarner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
D Leann LongBiostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Suzanne E JuddDepartment of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Virginia J HowardDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Timothy B PlanteLarner College of Medicine at the University of Vermont, Burlington, Vermont, USA.ORCID 0000-0001-9992-9597

Funding

Cardiovascular Research Institute of the University of VermontNIA NIH HHSNIH HHSNINDS NIH HHSU.S. Department of Health and Human Services
6 · The paper itself

Abstract

backgroundBlack US adults experience a greater hypertension burden and have lower levels of soluble receptors for advanced glycation end products (sRAGE). sRAGE may reduce inflammation, which is itself a hypertension risk factor. We hypothesized that higher sRAGE levels are associated with a lower risk of incident hypertension in a cohort of Black and White adults.

methodsThe REasons for Geographic and Racial Differences in Stroke (REGARDS) enrolled 30,239 Black and White adults from the contiguous United States in 2003-2007; a second visit occurred in 2013-2016. sRAGE was measured at baseline by ELISA in 4,400 participants attending both visits. Hypertension was defined as BP > 140/90 mm Hg or use of antihypertensive medications. Participants with baseline hypertension were excluded. Poisson regression estimated incident hypertension risk ratios (RR) by sRAGE levels, adjusting for confounders.

resultsAmong 1,799 participants without baseline hypertension (mean [SD] age 62 [8] years, 55% females, 25% Black), 46% of Black participants and 31% of White participants developed hypertension. Median sRAGE was lower in Black than White persons (P < 0.0001). Relative to quartile 1, White participants in quartile 4 of sRAGE had a 24% lower risk of incident hypertension (RR 0.76; 95% CI 0.59, 0.96) in a minimally adjusted model, but no differences in a fully adjusted model (0.81; 0.63 to 1.05). There was no association of sRAGE with hypertension in Black participants.

conclusionsHigher baseline sRAGE levels were not associated with lower risk of incident hypertension after adjusting for known confounders. Low sRAGE might represent adverse inflammation that drives hypertension rather than being a primary driver of hypertension development itself.

Indexed as

Blood PressureHypertensionReceptor for Advanced Glycation End ProductsAgedBiomarkersBlack or African AmericanFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsUnited StatesWhiteBiomarkersReceptor for Advanced Glycation End Productsblood pressurecohort studieshypertensioninflammationsRAGE

Identifiers

PMID40708351
PMCPMC12620019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.